Jeffrey Holzbeierlein, M.D., University of Kansas Medical Center, discusses how important it was that a multidisciplinary team came together to create the non-metastatic muscle-invasive bladder cancer guidelines.
Jeffrey Holzbeierlein, M.D., University of Kansas Medical Center, discusses how important it was that a multidisciplinary team came together to create the non-metastatic muscle-invasive bladder cancer guidelines.
A group of professionals from various organizations, such as the American Urologic Association and ASCO, as well as those working in medical and radiation oncology, and a patient advocate from the Bladder Cancer Advocacy Network (BCAN) all came together to form these guidelines, which are the first guidelines made for this disease type.
Including a team of professionals and advocates -- rather than just having a group of urologists make the guidelines -- gives the guidelines more validity and credibility, and helps to educate patients and professionals across the different realms of oncology.
FDA Approves 3 Treatments, Cancer Vaccine Shows Promise
December 20th 2023The Food and Drug Administration recently approved treatment for some patients with neuroblastoma, kidney cancer and bladder cancer. Elsewhere, a cancer vaccine made headlines for the treatment of patients with melanoma.
Listen
FDA Approves Opdivo Plus Chemo for Unresectable or Metastatic Bladder Cancer
March 7th 2024The Food and Drug Administration (FDA) has approved Opdivo (nivolumab) in combination with cisplatin and gemcitabine for the first-line treatment of adults with unresectable or metastatic bladder cancer, the agency has announced.
Read More